The positive clinical response to Dabrafenib in these BRAF V600E adult malignancies has opened doors to several trials of the drug in paediatric gliomas [71], in which the initial findings demonstrated that Dabrafenib in BRAF V600-relapsed or refractory pLGGs showed an overall response rate of 41% [82]. Here, BRAF is linked to central nervous system cancer.